InternationalUSRemember you can easily switch between MIP US and MIP International at any time

India: Novartis fights on in Gleevec battle


Novartis has now appealed to the Supreme Court in a bid to overturn the rejection of its controversial patent for Gleevec. Archana Shanker of Anand and Anand discusses the issues raised by the case

The speculation seemed to have come to an end on June 26 2009 when the Intellectual Property Appellate Board (IPAB) gave its decision on the Novartis patent application directed to the beta crystalline version of imatinib mesylate (Gleevec), refusing the patent application. Novartis then filed a special leave petition (SLP) before the Supreme Court, which has issued notice to the respondents in the matter (Union of India and others) to decide the issue of maintainability.

The facts of the Novartis pre-grant oppositions are well known and this article is only an attempt to summarise the issues and the propositions of law that have been discussed in the judgment.

By way of background, Novartis AG, a Swiss pharmaceutical company, applied for patent number 1602/MAS/1998 claiming Swiss priority of July 18 1997 for an invention directed to a "beta crystalline form of imatinib mesylate". Cancer Patient Aid Association (CPAA), NATCO Pharma, CIPLA...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Just been interviewing Fred Reinhart, president of @AUTM_Network V interesting chat about open innovation - will be on the site next week

Jun 30 2015 05:05 ·  reply ·  retweet ·  favourite
ManagingIP profile

New EU General Court rules effective tomorrow http://t.co/asyjufhrs9 More info here ($/trial) http://t.co/0P9ESxFke4 Imp't for OHIM appeals

Jun 30 2015 03:51 ·  reply ·  retweet ·  favourite
ManagingIP profile

Why biotechs may prefer trade secrets to patents - @mdloney reports from #BIO2015 http://t.co/n7MyHccpab ($/trial) http://t.co/8cTcxSHj9M

Jun 30 2015 02:04 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements